SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma gains on plan to expand product portfolio in the US

08 Jun 2017 Evaluate

Aurobindo Pharma is currently trading at Rs. 603.70, up by 5.65 points or 0.94% from its previous closing of Rs. 598.05 on the BSE.

The scrip opened at Rs. 603.00 and has touched a high and low of Rs. 606.75 and Rs. 598.75 respectively. So far 68301 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 895.00 on 06-Oct-2016 and a 52 week low of Rs. 504.00 on 29-May-2017.

Last one week high and low of the scrip stood at Rs. 606.75 and Rs. 576.00 respectively. The current market cap of the company is Rs. 35270.12 crore.

The promoters holding in the company stood at 51.87%, while institutions and non-institutions held 33.75% and 14.38% respectively.

Aurobindo Pharma is expanding its product portfolio in the US with high-value drugs. The portfolio mix is complemented with the introduction of high-value products and the future pipeline will include oncology, hormones, depot injections, inhalers, biosimilars, patches and films.

The addressable market for the company’s total 429 Abbreviated New Drug Applications (ANDAs) has been pegged at $91 billion, including $61 billion for the ANDAs which are under review and tentatively approved.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1488.50 9.95 (0.67%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×